ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
So what about immunotherapy?
The hot phrase in cancer treatment is immunotherapy right now. What does it mean for ALK+patients? Sometimes, you hear that immunotherapy does not work? But why are we trying to fund and are funding vaccines? Don’t vaccines work with the immune system? This short summary is to clarify these questions for you. There is an…
-
Dr. Vincent Lam at ALKtALK
Director, Esophageal Cancer Research Program, Assistant Professor of Oncology Expertise: Esophageal Cancer & Lung cancer Dr Lam: I am so excited to join your conversation tonight on a Sunday evening. I’m scrolling through five pages of people on the zoom call. It’s just amazing to see how committed and engaged you all are. That’s a…
-
Stronger Together: ALK+ (Virtual) Summit 2021 July 31 & Aug 1
TWO AMAZING DAYS of Knowledge, Hope, Sharing & Connection REGISTRATION IS FREE! DAY 1_SATURDAY AGENDA: (All times Eastern Standard)10:00am-11:00am (EST) Welcome! We are kicking off our ALK Summit 2021 with our ALK Summit Chair Amanda Nerstad, President Gina Hollenbeck and our keynote speaker, Teresa Graham, Head of Global Product Strategy with Roche Pharmaceuticals 11:15am-12:45am The…
-
Dr. Benjamin Levy & NPC Rasheda Persinger join ALKtALK
BENJAMIN PHILLIP LEVY, MD, Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology RASHEDA PERSINGER, Nurse Practitioner Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Deborah Kimmel, a patient since January 2018, gave an introduction. “Dr. Levy is one of the leading Thoracic…
-
ALK Genetics 101
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…
-
Hope for ALK+ NSCLC Patients
It’s important that we generate our own hope throughout the challenges and difficulties of ALK+ NSCLC. Oh yes, there is plenty to be hopeful about on the research and treatment fronts. The news about next-generation TKIs, chemotherapy, vaccines, a variety of promising trials; all give credence to the case for much longer survival than ever. …
-
Update on Clinical Trials currently recruiting for ALK-positive lung cancer
A new ALK inhibitor starts its clinical trials this month! TPX-0131 is an TKI ALK inhibitor designed to overcome multiple ALK resistance mutations. This first-in-human trial for ALK-positive lung cancer is now recruiting near Perth, Australia. Other sites for the FORGE-1 trial will be added in Australia and the U.S. over the next few months.…
-
Real World Data in Medical Research
What is real world data vs. on-paper data? Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share. That’s paper data. In real life, clinical doctors prescribe the medication and the end results for people are the real-world data. Most of the time, this section highlights…
-
Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK
Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great to be here tonight. It’s so nice to see so many familiar faces on the call. Being one of the recipients for the ALK Positive…